Cybin Inc. CEO To Present In Two Upcoming Investor Conferences

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Cybin CYBN, a biotechnology company focused on progressing psychedelic therapeutics, will be participating in two upcoming investor conferences. The company announced that CEO Doug Drysdale will be presenting virtually in a fireside chat during the Cantor Virtual Global Healthcare Conference and, during the Benzinga Healthcare Small-Cap Conference, Drysdale will be presenting and participating in a panel discussion.

The Benzinga conference is scheduled for Thursday, Sept. 30, 2021, and Drysdale’s presentation is scheduled for 12:15 p.m. ET. According to the announcement, Drysdale will also be involved in a panel discussion titled “Addressing Mental Health through Emerging Therapies” immediately following his presentation. On the same day, Drysdale will be presenting during the Benzinga conference; his presentation is slated to begin at 2 p.m. ET, with a replay of the presentation available for 90 days following the live webcast.

To view the full webcasts, visit https://ibn.fm/4SSfm and https://ibn.fm/a6SOQ

To view the full press release, visit https://ibn.fm/eElIj

About Cybin Inc.

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Image by David Mark from Pixabay

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsPenny StocksSmall CapEventsGeneralConferencesCybinInvestorBrandNetworkInvestorsPartner Content
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...